Publications & Presentations
Transplanted Organoids Empower Human Preclinical Assessment of Drug Candidate for the Clinic
Amy Westerling-Bui, Eva Maria Fast, Thomas Soare, Srinivasan Venkatachalan, Michael Deran, Alyssa Fanelli, Sergii Kyrychenko, Hien Hoang, Grinal Corriea, Wei Zhang, Maolin Yu, Matthew Daniels, Goran Malojcic, Xin-ru Pan-Zhou, Mark Ledeboer, Jean-Christophe Harmange, Maheswarareddy Emani, Thomas Tibbitts, John Reilly, Peter Mundel
Phase 1, Randomized, Placebo-Controlled Single-Ascending Dose Trial of GFB-024, a once-monthly CB1 inverse agonist, in Healthy Overweight and Obese Participants
Edwin Tucker, Gregory Gaich, Sanela Bilic, John Lawler, Yossi Dagon, Thomas A. Gustafson, Leslie Johnson, Lori Rudolph-Owen
Phase 1, Randomized, Controlled Trial of GFB-024, a Once-Monthly CB1 Inverse Agonist, in Healthy Overweight and Obese Participants and in Participants with Type 2 Diabetes Mellitus
Edwin Tucker, Gregory Gaich, Sanela Bilic, John Lawler, Yossi Dagon, Thomas A. Gustafson, Leslie Johnson, Lori Rudolph-Owen
Subset analysis of The HALO Survey evaluating the impact of side effects of medications in patients with glomerular disease
Amanda Grandinetti, Kirk Campbell, Agnes Costello, Kent Bressler, Jill Hammonds, Kristen Hood, Joseph Kennedy, Liz Melone, Shannon Mulroy, Dine Watson, Eric Duhaime
Discovery and Optimization of Highly Selective Inhibitors of CDK5
Matthew H. Daniels, Goran Malojcic, Susan L. Clugston, Brett Williams, Marie Coeffet-Le Gal, Xin-Ru Pan-Zhou, Srinivasan Venkatachalan, Jean-Christophe Harmange, Mark Ledeboer
GFB-887
Our lead product candidate, GFB-887 is designed specifically to treat people with kidney diseases associated with an over-activation of the TRPC5-1 pathway.
GFB-024
Our second product candidate is intended to treat patients with severe insulin resistant diabetic nephropathy (SIRDN) and CB1 pathway overactivation.